For the twelve months ended Sep 30, 2026, InMed Pharmaceuticals Inc. reported -$13.16M of net income.
INM revenue was $820.2K in fiscal Q2 2026 (ended Dec 31, 2025), down 26.2% from a year earlier and down 26.8% from the prior quarter. For the full fiscal 2025 it was $4.94M, up 7.5% from fiscal 2024. It rose in 3 of the last 4 fiscal years. Fiscal 2025 is the highest of the 5 fiscal years on file.
INM net income was -$2.33M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$1.73M a year earlier. For the full fiscal 2026 it was -$12.56M, compared with -$8.16M in fiscal 2025.
INM diluted EPS was -$0.42 in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$0.44 a year earlier. For the full fiscal 2026 it was -$3.12.
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | - | $4.94M | $4.60M | $4.14M | $1.09M | $1.90M | - |
| Cost of revenue | - | $3.24M | $3.50M | $2.73M | $545.9K | - | - |
| Gross profit | - | $1.71M | $1.10M | $1.40M | $543.5K | - | - |
| Research and development | $3.03M | $2.82M | $3.22M | $3.73M | $7.28M | $5.34M | $5.81M |
| Selling, general and admin | $6.66M | $5.41M | $5.80M | $5.85M | $6.87M | $4.48M | $3.23M |
| Operating income | - | - | - | -$7.95M | -$18.60M | -$10.20M | - |
| Pre-tax income | -$11.37M | -$8.69M | -$7.67M | -$7.93M | -$18.60M | - | - |
| Income tax | - | - | $7.1K | $13.1K | - | - | - |
| Net income | -$12.56M | -$8.16M | -$7.68M | -$7.95M | -$18.60M | -$10.20M | -$8.94M |
| EPS, basic | -$3.12 | -$8.36 | -$20.14 | -$65.00 | -$663.40 | -$759.20 | -$855.00 |
| EPS, diluted | -$3.12 | -$8.36 | -$20.14 | -$65.00 | -$663.40 | -$759.20 | -$855.00 |
| Diluted shares | 4.2M | 975,895 | 381,053 | 122,422.9 | 28,041.45 | 13,439.65 | 10,441.414 |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.19M | $10.74M | $6.57M | $8.91M | $6.18M | $7.36M | $5.81M |
| Short-term investments | $39.7K | $43.4K | $43.1K | $44.4K | $44.8K | $46.5K | $42.4K |
| Receivables | - | $465.1K | $352.8K | $260.4K | $88.0K | $11.9K | $45.3K |
| Inventory | - | $961.2K | $1.24M | $1.62M | $2.49M | - | - |
| Current assets | $2.68M | $12.87M | $8.69M | $11.33M | $9.60M | $8.38M | $6.31M |
| Total assets | $3.03M | $15.58M | $11.82M | $14.11M | $12.79M | $9.78M | $7.80M |
| Current liabilities | $1.96M | $1.84M | $1.97M | $2.00M | $3.32M | $2.22M | $1.68M |
| Total liabilities | $1.96M | $2.15M | $2.62M | $2.02M | $3.71M | $2.40M | $1.92M |
| Shareholders' equity | $1.08M | $13.43M | $9.21M | $12.09M | $9.08M | $7.38M | $5.88M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.64M | -$8.10M | -$6.99M | -$7.28M | -$15.58M | -$9.79M | -$7.37M |
| Capital expenditures | - | - | $9.3K | $160.0K | $39.1K | $1.7K | $42.6K |
| Free cash flow | - | - | -$7.00M | -$7.44M | -$15.62M | -$9.79M | -$7.42M |
| Investing cash flow | - | - | -$9.3K | -$661.8K | -$673.0K | -$1.7K | $3.79M |
| Financing cash flow | $94.5K | $12.27M | $4.65M | $10.68M | $15.07M | $10.85M | -$31.0K |
| Stock-based compensation | $106.9K | $119.3K | $137.7K | $278.2K | $697.9K | $610.2K | $994.4K |
| Depreciation and amortization | $205.3K | $212.8K | $219.6K | $202.2K | $185.7K | $120.9K | $112.4K |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | 7.5% | 11.2% | 279.6% | -42.8% | - | - |
| Gross margin | - | 34.5% | 23.9% | 33.9% | 49.9% | - | - |
| Operating margin | - | - | - | -192.2% | -1707.3% | -535.9% | - |
| Net margin | - | -165.1% | -166.9% | -192.2% | -1707.3% | -535.9% | - |
| Free cash flow margin | - | - | -152.1% | -180.0% | -1434.0% | -514.3% | - |
| Return on equity | -1168.4% | -60.8% | -83.4% | -65.7% | -204.9% | -138.3% | -152.1% |
| Return on assets | -414.5% | -52.4% | -64.9% | -56.3% | -145.5% | -104.3% | -114.6% |
| Current ratio | 1.37 | 6.99 | 4.41 | 5.66 | 2.89 | 3.78 | 3.77 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $820.2K | $1.12M | $1.30M | $1.26M | $1.11M | $1.26M | $1.28M | $1.17M | $1.24M |
| Cost of revenue | - | - | - | $636.0K | $717.0K | $728.1K | $1.09M | $650.8K | $771.2K | $817.0K | $883.1K | $916.1K |
| Gross profit | - | - | - | $184.2K | $403.2K | $576.7K | $175.6K | $460.9K | $493.4K | $466.1K | $289.5K | $324.1K |
| Research and development | $206.0K | $805.7K | $1.02M | $630.6K | $575.5K | $577.3K | $425.4K | $895.2K | $700.1K | $658.9K | $656.8K | $609.8K |
| Selling, general and admin | $1.80M | $2.36M | $1.74M | $1.62M | $1.24M | $1.26M | $1.58M | $1.72M | $1.49M | $1.76M | $1.37M | $1.36M |
| Pre-tax income | -$2.00M | -$4.84M | -$2.79M | -$2.03M | -$1.83M | -$1.83M | -$2.07M | -$2.58M | -$1.68M | -$1.93M | -$1.72M | -$1.48M |
| Net income | -$2.33M | -$5.84M | -$2.97M | -$2.03M | -$1.73M | -$1.79M | -$2.12M | -$2.58M | -$1.68M | -$1.94M | -$1.72M | -$1.48M |
| EPS, basic | -$0.42 | -$1.44 | -$0.73 | -$0.51 | -$0.44 | - | -$1.94 | -$3.64 | -$2.71 | - | -$3.58 | -$3.71 |
| EPS, diluted | -$0.42 | -$1.44 | -$0.73 | -$0.51 | -$0.44 | - | -$1.94 | -$3.64 | -$2.71 | - | -$3.58 | -$3.71 |
| Diluted shares | 5.5M | - | 4.0M | 4.0M | 4.0M | - | 1.1M | 706,546 | 620,127 | - | 480,649 | 398,673 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.09M | $2.19M | $5.16M | $6.95M | $8.68M | $10.74M | $4.68M | $3.42M | $5.58M | $6.57M | $7.60M | $9.53M |
| Short-term investments | $40.3K | $39.7K | $41.6K | $42.7K | $42.9K | $43.4K | $40.6K | $40.8K | $43.2K | $43.1K | - | $44.5K |
| Receivables | - | - | - | $183.0K | $343.5K | $465.1K | $367.8K | $262.6K | $284.7K | $352.8K | - | $372.9K |
| Inventory | - | - | - | $947.9K | $890.8K | $961.2K | $814.0K | $1.10M | $1.22M | $1.24M | - | $744.8K |
| Current assets | $1.26M | $2.68M | $6.89M | $8.79M | $10.80M | $12.87M | $6.41M | $5.47M | $7.28M | $8.69M | - | $11.81M |
| Total assets | $1.31M | $3.03M | $9.13M | $11.19M | $13.36M | $15.58M | $9.28M | $8.50M | $10.47M | $11.82M | - | $15.26M |
| Current liabilities | - | $1.96M | $2.21M | $1.48M | $1.55M | $1.84M | $1.84M | $1.79M | $1.44M | $1.97M | - | $1.68M |
| Total liabilities | $2.51M | $1.96M | $2.24M | $1.60M | $1.77M | $2.15M | $2.26M | $2.32M | $2.07M | $2.62M | - | $2.48M |
| Shareholders' equity | -$1.20M | $1.08M | $6.89M | $9.59M | $11.59M | $13.43M | $7.02M | $6.18M | $8.40M | $9.21M | $11.10M | $12.77M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.14M | -$2.96M | -$1.70M | -$2.05M | -$1.93M | -$2.11M | -$1.66M | -$2.50M | -$1.83M | -$1.03M | -$1.93M | -$1.85M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | $0 | $2 | - |
| Free cash flow | - | - | - | - | - | - | - | - | - | -$1.03M | -$1.93M | - |
| Investing cash flow | $2.4K | - | - | - | - | - | - | - | - | $0 | -$2 | - |
| Financing cash flow | $40.0K | -$1 | $231.7K | $0 | -$137.2K | $8.17M | $2.92M | $338.5K | $838.2K | $176 | $0 | - |
| Stock-based compensation | $16.4K | $22.6K | $38.8K | $25.3K | $20.2K | $26.7K | $40.5K | $23.2K | $29.0K | $39.0K | $55.3K | $18.3K |
| Depreciation and amortization | $168 | $48.4K | $51.7K | $53.2K | $53.2K | $52.8K | $51.7K | $53.2K | $54.6K | $54.8K | $54.8K | $55.2K |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -26.2% | -11.4% | 1.7% | 7.6% | -10.4% | 40.2% | -44.5% | 13.4% | 164.0% |
| Gross margin | - | - | - | 22.5% | 36.0% | 44.2% | 13.9% | 41.5% | 39.0% | 36.3% | 24.7% | 26.1% |
| Net margin | - | - | - | -247.3% | -154.2% | -137.1% | -168.1% | -231.6% | -132.7% | -151.0% | -146.9% | -119.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -80.2% | -165.0% | - |
| Current ratio | - | 1.37 | 3.11 | 5.94 | 6.95 | 6.99 | 3.49 | 3.05 | 5.07 | 4.41 | - | 7.03 |
Source: XBRL data InMed Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Sep 23, 2022; 1-for-20, first reported Nov 14, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| INM | - | - | -$13.16M | - | $8.5M |
| CRBP | - | - | -$101.90M | - | $68.1M |
| JAZZ | $4.72B | +13.5% | $205.95M | 4.4% | $15.63B |
| TLRY | $963.10M | +15.9% | -$164.22M | -17.1% | $421.2M |